Median age | 64.6 |
---|---|
Male | 52.8% |
Stage | Â |
I-II | 46.3% |
III-IV | 53.7% |
Primary therapy | Â |
CEOP | 17.6% |
CHOP | 63.0% |
CHOEP | 18.5% |
CHOP + IMVP-16 | 0.9% |
Radiotherapy | 53.7% |
Rituximab | 100% |
GC phenotype | 33.3% |
Non-GC phenotype | 57.3% |
B-symptoms | 37.0% |
LD high | 64.8% |
WHO > 1 | 19.4% |
Extranodal involvement > 1 | 22.6% |
IPI | Â |
0-2 | 59.0% |
3 | 18.1% |
4-5 | 22.8% |